Advertisement
BMY or INSM or MRK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Insmed (INSM) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- BMY trades at a P/E of ~17x with ~14% YTD gains, buoyed by growth portfolio momentum amid legacy declines.
- INSM shows explosive 1-year returns over 80% but negative YTD amid volatility, driven by Brinsupri launch exceeding $1B 2026 guidance.
- MRK leads stability with ~10-15% YTD gains, P/E ~16x, and Keytruda fueling oncology dominance despite future patent risks.
- BMY and MRK offer dividends (4.15% and ~2.9%), contrasting INSM's growth focus without payouts.
- Market caps: MRK ~$290B dwarfs BMY ~$122B and INSM ~$30B, implying lower beta risk for larger peers.
- Recent sentiment favors pipeline catalysts, with AI tools highlighting momentum in pharma volatility.
Introduction
This comparison examines BMY, a diversified biopharma giant; INSM, a biotech focused on rare pulmonary diseases; and MRK, a leader in oncology and vaccines. Traders seeking relative performance in healthcare may value their contrasts in scale, growth trajectories, and risk amid recent pipeline advancements and market rotations. Investors tracking stock comparisons for momentum, valuation sensitivity, and sector exposure will find insights into current positioning, particularly as AI-driven tools spotlight trending opportunities in volatile conditions.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company specializing in oncology, immunology, cardiovascular, and hematology therapies. In recent market activity, shares gained around 11% over the past month, outperforming the industry amid positive Phase 2 data for Reblozyl and growth portfolio traction offsetting legacy drug declines. YTD returns hover near 14%, with a market cap of ~$122B and P/E ~17x. Sentiment has shifted positively on pipeline promise and dividend yield over 4%, though patent cliffs pose near-term pressures. Trading at a forward discount, BMY reflects value amid broader pharma stability.
INSM Overview and Recent Performance
Insmed (INSM) develops therapies for rare diseases, notably pulmonary conditions, with flagship products ARIKAYCE and Brinsupri. Recent weeks saw volatility, with YTD down ~18% after a strong 1-year run exceeding 80%, tied to Brinsupri's "stunning" launch generating $144M in its first full quarter and 2026 guidance over $1B. Market cap ~$30B, no P/E due to losses, but revenue doubled outlook signals acceleration in Japan/Europe. Performance reflects biotech risk-reward, with high beta amplifying momentum swings in respiratory innovations.
MRK Overview and Recent Performance
Merck & Co. (MRK) excels in oncology via Keytruda, vaccines, and animal health. Recent activity shows YTD gains ~10-15%, with 1-year up ~28%, supported by Q4 beats, Keytruda growth to $8.37B, and new launches like Winrevair. Market cap ~$290B, P/E ~16x. Sentiment benefits from pipeline depth (80+ Phase III trials) and collaborations, tempering Gardasil softness. Lower beta underscores defensive positioning in large-cap pharma.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from hundreds of AI Trading Bots scanning thousands of tickers for optimal strategies in current conditions. These bots employ diverse styles like swing trading dips (TA), trend following (FA), hedging, and volatility plays across 5-60min timeframes, delivering annualized returns up to +220%, win rates 52-95%, and profit factors to 25+. Recent standouts include aerospace/defense (+124%), semiconductors, and infrastructure bots with 70-90% wins, outperforming S&P in volatility. Only the best-suited for momentum, rotations, and dips earn trending status. Explore these for data-driven edges in stocks like BMY, INSM, and MRK.
Head-to-Head Comparison
BMY and MRK anchor large-cap pharma with oncology cores, but MRK's Keytruda ($35B peak) drives superior growth vs. BMY's Reblozyl offsetting Eliquis erosion. INSM offers biotech upside via Brinsupri but lacks profitability. Momentum favors MRK (28% 1Y) over BMY (5-12%) and volatile INSM (80%+ 1Y, -18% YTD). Risks: BMY/ MRK face 2028 cliffs; INSM execution in rares. Valuations near 16-17x P/E for giants vs. N/A for INSM; BMY yields best. Sentiment tilts stable MRK over value BMY and growth INSM.
Tickeron AI Verdict
Tickeron’s AI leans toward MRK for its trend consistency, lower beta stability, Keytruda catalysts, and relative positioning amid pharma volatility. Observable momentum and pipeline depth suggest higher probability of outperformance versus BMY's value tilt or INSM's biotech swings, though diversified bots could capture all three.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s), and MRK’s FA Score reflects 4 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- INSM’s FA Score: 0 green, 5 red.
- MRK’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while INSM’s TA Score has 3 bullish TA indicator(s), and MRK’s TA Score reflects 4 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 4 bearish.
- INSM’s TA Score: 3 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +2.64% price change this week, while INSM (@Biotechnology) price change was -6.67% , and MRK (@Pharmaceuticals: Major) price fluctuated -1.94% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
BMY is expected to report earnings on Apr 30, 2026.
INSM is expected to report earnings on Apr 30, 2026.
MRK is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BMY | INSM | MRK | |
| Capitalization | 123B | 31.2B | 294B |
| EBITDA | 15.2B | -1.18B | 28.3B |
| Gain YTD | 14.032 | -16.985 | 13.958 |
| P/E Ratio | 17.39 | N/A | 16.36 |
| Revenue | 48.2B | 606M | 65B |
| Total Cash | N/A | 1.43B | N/A |
| Total Debt | 47.1B | 587M | 49.3B |
BMY | INSM | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 68 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 76 Overvalued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 37 | 48 | |
SMR RATING 1..100 | 23 | 100 | 25 | |
PRICE GROWTH RATING 1..100 | 21 | 49 | 16 | |
P/E GROWTH RATING 1..100 | 66 | 100 | 28 | |
SEASONALITY SCORE 1..100 | n/a | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (21) in the Pharmaceuticals Major industry is in the same range as BMY (41) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INSM (76) in the Biotechnology industry. This means that MRK's stock grew similarly to BMY’s and somewhat faster than INSM’s over the last 12 months.
INSM's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as MRK (48) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BMY (81) in the Pharmaceuticals Major industry. This means that INSM's stock grew similarly to MRK’s and somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (23) in the Pharmaceuticals Major industry is in the same range as MRK (25) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that BMY's stock grew similarly to MRK’s and significantly faster than INSM’s over the last 12 months.
MRK's Price Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as BMY (21) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INSM (49) in the Biotechnology industry. This means that MRK's stock grew similarly to BMY’s and somewhat faster than INSM’s over the last 12 months.
MRK's P/E Growth Rating (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (66) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that MRK's stock grew somewhat faster than BMY’s and significantly faster than INSM’s over the last 12 months.
| BMY | INSM | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 42% | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 48% | 3 days ago 78% | 3 days ago 62% |
| Momentum ODDS (%) | 3 days ago 45% | 3 days ago 74% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 66% | 3 days ago 59% |
| TrendWeek ODDS (%) | 3 days ago 52% | 3 days ago 72% | 3 days ago 48% |
| TrendMonth ODDS (%) | 3 days ago 54% | 3 days ago 74% | 3 days ago 52% |
| Advances ODDS (%) | 3 days ago 54% | 19 days ago 71% | 18 days ago 52% |
| Declines ODDS (%) | 7 days ago 53% | 4 days ago 73% | 4 days ago 50% |
| BollingerBands ODDS (%) | 3 days ago 48% | 3 days ago 70% | 3 days ago 69% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 84% | 3 days ago 54% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHX | 27.99 | 0.34 | +1.23% |
| Schwab US Large-Cap ETF™ | |||
| CA | 25.05 | 0.10 | +0.41% |
| Xtrackers California Municipal Bond ETF | |||
| BSMW | 25.14 | 0.07 | +0.27% |
| Invesco BulletShares 2032 Muncpl Bd ETF | |||
| LVLN | 24.71 | 0.06 | +0.24% |
| State Street SPDR S&P Leveraged Ln ETF | |||
| PHK | 4.67 | -0.03 | -0.64% |
| PIMCO High Income Fund | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +2.05% | ||
| PFE - BMY | 63% Loosely correlated | +1.25% | ||
| MRK - BMY | 60% Loosely correlated | +3.13% | ||
| AMGN - BMY | 58% Loosely correlated | +1.69% | ||
| BIIB - BMY | 54% Loosely correlated | +0.76% | ||
| ABBV - BMY | 54% Loosely correlated | -0.29% | ||
More | ||||